Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research

Pre-Made Eftilagimod Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting MH2 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eftilagimod alpha is a large-molecule cancer drug consisting of the four extracellular domains of lymphocyte activation gene-3 (LAG-3) fused to the Fc region of an IgG1(LAG-3Ig). Eftilagimod alpha binds preferentially to a subset of MHC class II molecules that are enriched in lipid rafts and/or composed of stable peptide-MHC II (pMHCII) complexes. On T cells, membrane-anchored LAG-3 is an inhibitory receptor downregulating T-cell receptor (TCR) signaling. Eftilagimod alpha is an MHC class II agonist and therefore a dendritic-cell activator, causing increased antigen presentation to cytotoxic (CD8+) T cells. In the absence of antigen presentation via MHC class II molecules, Eftilagimod alpha reactivates dormant antigen-experienced memory T cells, allowing them to recognize their antigen targets at the tumor site.